Rezultati pretraživanja
  1. prije 9 sati

    New review: the nocebo effect may contribute to treatment failures when patients are switched from an originator to a . Better patient education is among the authors' recommendations

  2. prije 12 sati

    is continuing to expand its range of research grade antibodies. We now offer 154 biosimilar antibodies covering 20 targets that are conjugated or unconjugated to fit your needs. View products:

  3. The market in is projected to quadruple from USD 2 billion in 2018 to USD 8.1 billion in 2025.

  4. prije 12 sati

    : and draw a line on anticompetitive practices in the complex market. Read more:

  5. The regulatory submission is supported by a comprehensive data package demonstrating biosimilarity with PF-05280586 to reference rituximab, including results from the REFLECTIONS B3281006 study

  6. prije 14 sati

    Do you ever wonder where the US market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the industry.

  7. prije 15 sati

    View the top ten ranked by savings. The presence in the market of FDA-approved safe and effective generic and medicines saves America's patients more money every year.

  8. 5. velj

    AAM and its looks forward to continuing to work closely with the Administration to increase patient access to critical and live-saving treatments, including .

  9. 4. velj
  10. 4. velj

    The European Medicines Agency’s Committee for Medicinal Products for Human Use has a positive opinion for a Marketing Authorization Application for the rituximab PF-05280586 for non-Hodgkin lymphoma, CLL, RA, GPA, MPA, and pemphigus vulgaris

  11. 4. velj

    "...claiming that a is, in general, less safe or less effective than the reference product ...simply because the is licensed for fewer indications than the reference product would be misleading"

    Prikaži ovu nit
  12. 4. velj

    "...representations or suggestions that create an impression that a is not highly similar to its reference product are likely to be false or misleading."

    Prikaži ovu nit
  13. 4. velj

    FDA Guidance on and misinformation: "..representing or suggesting that a reference product is safer or more effective than its product... are likely to be false or misleading"

    Prikaži ovu nit
  14. 3. velj

    Want to know more about future opportunities? Join Aurelio Arias at his presentation on the 'Global Outlook for Biologics and Biosimilars' at 2020

  15. 2. velj
  16. As Ontario considers forced to switch policy, open letter asks and to review evidence and alternatives to save money

  17. 31. sij
  18. Pfizer Inc. - Pfizer Receives Positive CHMP Opinion of the European Medicines Agency for Oncology RUXIENCE™ (rituximab)

  19. 31. sij

    The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion for our third therapeutic . Find out more:

  20. Read our analysis of a potential subgroup inclusion in a phase III study & our counterintuitive solution.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.